Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post Menopausal Osteoporosis Clear all
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

NCT00048074
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Irvine, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

NCT02478879
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
ZP-PTH, FORTEO
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices

NCT00661856
View directory record Official record
Conditions
Osteoporosis
Interventions
Soy protein
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
55 Years to 72 Years · Female only
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 20, 2008 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

NCT02604836
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
142
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 2:24 PM EDT
Completed No phase listed Observational

A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

NCT00399321
View directory record Official record
Conditions
Postmenopausal Bone Loss, Breast Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

NCT00927186
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Teriparatide, Zoledronic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

NCT00377234
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Risedronate, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
48
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
Up to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

NCT00557310
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • Lakewood, Colorado • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass

NCT00489424
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, Acetaminophen, Fluvastatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 79 Years · Female only
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Http://www.osteoporosisclinicalresearch.com, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

NCT02598934
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
107
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jun 10, 2026, 2:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison Study of PTHrP and PTH to Treat Osteoporosis

NCT00853723
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone related protein(1-36), Parathyroid hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 4 Interventional

Long Term Effects of Raloxifene Treatment on Bone Quality

NCT00532428
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

NCT00383422
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Jun 10, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 10, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jun 10, 2026, 2:24 PM EDT